An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY1161909 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2017
At a glance
- Drugs BAY 1161909 (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 29 Nov 2017 Status changed from active, no longer recruiting to completed.
- 30 May 2017 Planned End Date changed from 1 Apr 2017 to 21 Dec 2017.
- 30 May 2017 Planned primary completion date changed from 1 Apr 2017 to 7 Dec 2017.